Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells

Oncogene volume 23, pages 7651–7659 (2004)Cite this article

Abstract

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β superfamily and signal through a number of membrane receptors. We have previously demonstrated that the loss of expression of BMP receptors (BMPRs) type IA, -IB, and -II (BMP-RIA, -RIB, and -RII) correlates with Gleason score in prostate cancer patients. To evaluate the prognostic value of this observation, we used immunohistochemistry to investigate the expression of BMPRs in association with disease progression in 60 patients. The results demonstrated a significant association between the loss of expression of the three BMPRs and Gleason score and clinical stage. However, only the loss of expression of BMP-RII showed a statistically significant association with 5-year survival rate (P<0.05) and biochemical recurrence-free rate following radical prostatectomy (P<0.005). To elucidate the effect of an abnormal BMP signaling in prostate cancer cells, we transfected dominant-negative BMP-RII (BMP-RIIDN) into the human prostate cancer cell line, PC3M. When a stable clone overexpressing BMP-RIIDN was inoculated subcutaneously into nude mice, the tumor growth rate was approximately 10 times that of control and parental cell line. These observations, taken together, indicate that the loss of BMP-RII expression as measured by immunohistochemistry may be a prognostic marker in prostate cancer patients, and that the loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE and Hamdy FC . (1998). Br. J. Cancer, 78, 1219–1223.

  • Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L . (1995). Cancer Res., 55, 4623–4626.

  • Brubaker KD, Corey E, Brown LG and Vessella RL . (2004). J. Cell Biochem., 91, 151–160.

  • Buckley S, Shi W, Driscoll B, Ferrario A, Anderson K and Warburton D . (2004). Am. J. Physiol. Lung Cell Mol. Physiol., 286, L81–86.

  • Derynck R, Akhurst RJ and Balmain A . (2001). Nat Genet., 29, 117–129.

  • Foletta VC, Lim MA, Soosairaiah J, Kelly AP, Stanley EG, Shannon M, He W, Das Supratik, Massague J and Bernard O . (2003). J. Cell Biol., 162, 1089–1098.

  • Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE and Robson CN . (1997). Cancer Res., 57, 4427–4431.

  • Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ and Mundy GR . (1994). Prostate, 24, 204–211.

  • Hogan BL . (1996). Genes Dev., 10, 1540–1594.

  • Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O’Neill GF, Kooner R, Stricker PD, Grygiel JJ and Sutherland RL . (2004). Prostate, 59, 234–242.

  • Ide H, Katoh M, Sasaki H, Yoshida T, Aoki K, Nawa Y, Osada Y, Sugimura T and Terada M . (1997a). Oncogene, 14, 1377–1382.

  • Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T and Terada M . (1997b). Cancer Res., 57, 5022–5027.

  • Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ . (2003). CA. Cancer J. Clin., 53, 5–26.

  • Kawamura C, Kizaki M and Ikeda Y . (2002). Leuk. Lymphoma, 43, 635–639.

  • Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M and Lee C . (1996). Cancer Res., 56, 44–48.

  • Kim IY, Lee D-H, Ahn H-J, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK and Morton RA . (2000). Cancer Res., 60, 2840–2844.

  • Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan WM, Morton RA and Kim SJ . (2003). Clin. Cancer Res., 9, 6046–6051.

  • Lamm MI, Podlasek CA, Barret DH, Lee J, Clemens JQ, Hebner CM and Bushman W . (2001). Dev. Biol., 232, 301–314.

  • Liu F, Ventura F, Doody J and Massague J . (1995). Mol. Cell Biol., 15, 3479–3486.

  • Masuda H, Fukabori Y, Nakano K, Shimizu N and Yamanaka H . (2004). Prostate, 59, 101–106.

  • Masuda H, Fukabori Y, Nakano K, Takezawa Y, Suzuki T and Yamanaka H . (2003). Prostate, 54, 268–274.

  • Pouliot F, Blais A and Labrie C . (2003). Cancer Res., 63, 277–281.

  • Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC and Morrell NW . (2002). Hum. Mol. Genet., 11, 1517–1525.

  • Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM and Pang RHL . (1992). J. Bio. Chem., 267, 20352–20362.

  • Sintich SM, Lamm ML, Sensibar JA and Lee C . (1999). Endocrinology, 140, 3411–3415.

  • ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Esterez M, Riddle DL, Ichijo H, Heldin CH and Miyazono K . (1994). J. Biol. Chem., 269, 16988–16989.

  • Thomas R, Anderson WA, Raman V and Reddi AH . (1998). Prostate, 37, 236–245.

  • Wen XZ, Miyake S, Akiyama Y and Yuasa Y . (2004). Biochem. Biophys. Res. Commun., 316, 100–106.

  • Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM and Wang FA . (1988). Science, 242, 1528–1534.

  • Yamada N, Kato M, ten Dijke P, Yamashita H, Sampath TK, Heldin CH, Miyazono K and Funa K . (1996). Br. J. Cancer, 73, 624–629.

  • Yamashita H, ten Dijke P, Heldin CH and Miyazono K . (1996). Bone, 19, 569–574.

  • Yonemori K, Imamura T, Ishidou Y, Okano T, Matsunaga S, Yoshida H, Kato M, Sampath TK, Miyazono K, ten Dijke P and Sakou T . (1997). Am. J. Pathol., 150, 1335–1347.

  • Zhao G-Q . (2003). Genesis, 35, 43–56.

Download references

Author information

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, Houston, 77030, TX, USA

    Isaac Yi Kim, Moses M Kim & Ronald A Morton

  2. Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, 20892, MD, USA

    Isaac Yi Kim, Dug Keun Lee & Seong Jin Kim

  3. Department of Urology, Ewha Women’s University, Seoul, Korea

    Dong-Hyeon Lee

  4. Department of Urology, Asan Medical Center, Seoul, Korea

    Han-Jong Ahn

  5. Department of Urology, University of California, Irvine, Orange, 92868, CA, USA

    Isaac Yi Kim

Authors
  1. Isaac Yi Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong-Hyeon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dug Keun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Han-Jong Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Moses M Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seong Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ronald A Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald A Morton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, I., Lee, DH., Lee, D. et al. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23, 7651–7659 (2004). https://doi.org/10.1038/sj.onc.1207924

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207924

Keywords

Search

Advanced search

Quick links